Merck Cuts 150 Jobs at HPV Vaccine Plant as Global Gardasil Sales Fall 39%

The ​layoffs will be effective in May, according to the notice.

Written By :  sheeba farhat
Published On 2026-02-28 14:30 GMT   |   Update On 2026-02-28 14:30 GMT

Bengaluru: Merck will lay off about 150 employees across its facility in North Carolina that manufactures its human papillomavirus vaccine, Gardasil, according to a notice filed in the state's database this week.

Shares of Merck were up 3% in afternoon trading.

Gardasil ‌has ⁠been one ⁠of Merck's top growth drivers after blockbuster cancer immunotherapy Keytruda, ​and much of its international growth has come from China. But ​the company halted shipments of the vaccine to China last year due to weak demand, driving a 39% ​slump in the shot's global sales ⁠in 2025.

The ‌vaccine protects against HPV infections ​that can ​lead to cervical, vulvar, vaginal and anal ⁠cancers. The U.S. also overhauled its long-standing childhood immunization ​schedule last month to recommend a single ​HPV vaccine dose instead of the approved two- or three-shot regimen. Gardasil is the only HPV vaccine licensed in the country.

Merck's management last month said Gardasil was no longer a key growth driver ‌for the company.

"We continuously assess our operations and evolving business needs and adjust as needed ​to ensure ​the effectiveness ⁠of our manufacturing network in delivering reliable, compliant supply of our medicines and vaccines," a company spokesperson told Reuters on Friday.

The ​layoffs will be effective in May, according to the notice.

As of December 31, 2025, the company had about 30,000 employees in the U.S., including Puerto Rico, according to a regulatory filing.

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News